NIH | National Cancer Institute | NCI Wiki  

Versions Compared

Old Version 1

changes.mady.by.user Kuffel, Gina (NIH/NCI) [C]

Saved on

compared with

New Version 2

changes.mady.by.user Kuffel, Gina (NIH/NCI) [C]

Saved on

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

Anchor
maincontent
maincontent

Date

Attendees

Committee MemberPresentAbsent
Kuffel, Gina (NIH/NCI) [C]
X
Kim, Erika (NIH/NCI) [E] X
Toby HechtX
Connie SommersX
Amy Leblanc
X
Igor KuzminX
Warren KibbeX
Matthew BreenX
Michael OlinX

...

Goals

  • Discuss the next 5 years for ICDC in preparation of the new task order

Discussion items

ItemWhoNotes
Integrating environmental exposures of human cancer patients with canines

Matthew Breen 

  • Human urothelial cancers with dogs that live in their homes
  • Dog omics that share the same environmental exposure as a human individual with cancer
  • Longitudinal studies across these dogs
  • Having an integrated canine commons at the NCI can be a hub for federal and privately funded studies
  • Signatures of lung cancers of smokers vs. someone exposed to smoke, can be validated using canines
  • Toxic compounds in clothing
Cellular Data (Flow Cytometry, Nano String Data)Michael Olin
  • Raw data from the flow cytometer so that people can generate their own plots
  • How can subsets be looked at
Workshop for Immuno-Oncolgy Data Analytics Erika Kim
  • IO data for humans and canines
Non-Cancer Diseases

Toby


Pharma-specific Focus Group

Amy

  • Certain tools and data
  • Immune landscape
  • Comparative nanostring IO cell landscapes
  • Landscape of IHC, Flow, and tools in specific canine tissues and cell types
  • Pharma needs to see placebo groups and to inspect efficacy signals with a set of retractable biomarkers
  • Pharma is looking for supplemental animal model
  • Jax labs may have some immunological data to submit
  • Dose optimization strategies
  • What does the FDA want to see as they are getting more molecularly targeted agents

Minutes (Not Verbatim)

Toby - We don't have sequencing data for comparing before and after therapy to detect genomic changes

...

Amy - Friend from Bristol Meyers Squib reached out to better understand relationsips with pharma, maybe we should put together a panel of pharma folks to see if they can have a focus group to determine data and tooling would be useful to that community.

Action items

  •  Erika to invite Toby and Connie to Immuno-Oncology Workshop

...